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Abstract
Background: The global economic crisis imposes severe restrictions on healthcare budgets, limiting the coverage
of new interventions, even when they are cost-effective. Our objective was to develop a tool that can assist
decision-makers in comparing the impact of medical intervention alternatives on the entire target population,
under a pre-specified budget constraint.
Methods: We illustrated the tool by using a target population of 1,000 patients, and a budget constraint of
$1,000,000. We compared two intervention alternatives: the current practice that costs $1,000 and adds 0.5
quality-adjusted-life-years (QALYs) per patient and a new technology that costs 100 % more, and provides
20 % more QALYs per patient. We also developed a formula for defining the maximum premium price for a
higher-cost/higher-effectiveness intervention that can justify its adoption under a constrained budget.
Results: Using the new therapy will add 300 QALYs, compared to 500 QALYS when using the lower-cost,
lower-effective intervention, despite a favorable incremental cost-effectiveness ratio (ICER) of $10,000. The
maximum price for the higher-efficacy therapy that will preserve the target population outcomes is 20 %
higher than the lower-cost therapy.
Conclusions: Although an intervention associated with higher costs and higher efficacy may have an
acceptable ICER, it could provide inferior outcomes in the target population under budget constraints,
depending on the relative effectiveness and costs of the interventions. The cost premium that can be
justified for a higher-efficacy intervention is directly correlated to its effectiveness premium. Using the
proposed tool may assist decision-makers in improving overall healthcare outcomes, especially in times
of economic downturn.
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Background
Promoting health equity can improve the population’s
overall health outcomes
The use of innovative medical technologies has signifi-
cantly improved population’s health outcomes, but this
improvement came with escalating healthcare costs [1].
The recent global economic crisis imposed severe re-
strictions on public budgets allocated to healthcare and
health spending growth has leveled off in many coun-
tries in the last few years, as shown in Fig. 1 [2]. Thus,
there is a need to continue the improvement of health
outcomes while containing health budgets. Current
healthcare policies, however, are very far from maximizing
the health outcomes of the population within the given
budgets. One option for achieving this goal is to reallocate
resources to interventions that provide the most “value for
money”. In this regard, Chambers et al. [3] have recently
suggested that more effective allocation of budgets may
yield an additional 1.8 million quality-adjusted life-years
(QALYs) in the US Medicare population, while maintain-
ing the same spending. Another policy may be providing
the population with slightly less effective medical inter-
ventions but at significantly lower cost, thus enabling ef-
fective treatment for a wider population. A recent study
has presented the advantages of using this approach, by
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analyzing the utilization patterns of biologic drugs to
avoid blindness due to age-related macular degeneration
or clinically significant diabetic macular edema [4]. The
authors demonstrated potential savings of $29B over the
course of 10 years by using a forty times less expen-
sive drug (bevacizumab), which has minor differences
in adverse events.
One could argue that it is mandatory for physicians to
provide the best available medicine to their patients, or
at least inform them that such a medicine is available.
However, the counter claim is that from a broader soci-
etal perspective, it is more important to achieve equity
in the supply of medical innovations. These claims have
previously been observed and discussed in the Prospect-
ive Urban Rural Epidemiological (PURE) study [5]. The
study recruited individuals in countries at various stages
of economic development, to assess the rates of use of
proven and effective secondary cardiovascular preven-
tion drugs. The authors concluded that because the use
of secondary prevention medications is low worldwide,
especially in low-income countries and rural areas, sys-
tematic approaches are needed to improve the long-
term use of basic, inexpensive and effective drugs. Al-
though lower quality, lower cost products are very com-
mon in many markets (e.g., consumer electronics, car
safety measures, furniture), barriers remain for using
such products in health care. Indeed, only very few cost-
effectiveness analyses demonstrated cost-savings while
providing (acceptable) inferior outcomes [5], and this ap-
proach is not implemented in most developed countries.
In this study, we first review the limitations of current
health technology assessment (HTA) models in provid-
ing decision-makers with tools that may assist them in
maximizing population’s health under restricted budgets.
We then develop an analytic framework for comparing
and assessing the impact of alternative interventions
under pre-specified budget constraints; one providing an
effective and expensive intervention to a limited patient
population and the other providing slightly less effective
but substantially cheaper intervention to a wider target
population. We argue that a widespread use of less effect-
ive and lower cost treatment alternatives may provide bet-
ter health outcomes to the society. Our proposed model is
probably one of the first to combine both the cost-
effectiveness and the budget impact of an alternative.
Limitations of cost-effectiveness analysis
Economic analyses and decisions on adoption of innova-
tive technologies have an important impact on society's
budgets and well-being. Health technology assessment
(HTA) assesses the short and long-term consequences of
using technologies in health care and provides policy-
makers with information on competing policy alterna-
tives [6]. While HTA includes various aspects related to
the use of technologies in health care, most analyses
focus on economic evaluations (e.g., cost-effectiveness
analysis) and the resources needed to implement an
intervention in clinical practice (e.g., budget impact ana-
lysis). Cost-effectiveness analysis (CEA) is an analytic
tool that quantifies the added expenditure necessary to
obtain a unit of health benefit, typically measured in
quality-adjusted life-years (QALYs) gained. Table 1 illus-
trates the four quadrants of the cost-effectiveness plane.
Interventions that are associated with lower costs and
Fig. 1 Annual Growth in public expenditures, Average OECD
Table 1 Distribution of Cost-Effectiveness studies
Quadrant Efficacy Cost % of CE studies
North East Better Higher 72 %
North West Lower Higher 10 %
South East Higher Lower 16 %
South West Lower Lower 2 %
Arbel and Greenberg International Journal for Equity in Health  (2016) 15:33 Page 2 of 7
higher effectiveness (dominant) should be adopted, while
those associated with higher costs and lower effectiveness
(dominated) should be rejected. Although in many coun-
tries there is no accepted threshold value identifying alter-
natives deemed cost-effective, several arbitrary thresholds
have been suggested [7–9], typically ranging from $50,000
to $150,000. There is no guidance on the “right” decision
for interventions that are less effective and less expensive
compared with an accepted alternative.
For a medical innovation to be widely adopted into rou-
tine practice, a “new and improved” reputation is custom-
arily required [10]. A review of published cost-effectiveness
analyses revealed that the majority of interventions exam-
ined are associated with higher costs and better outcomes,
and only approximately 2 % of CEAs present interventions
that are cost-saving while providing (acceptably) inferior
outcomes [5] as presented in Table 1.
The use of the current cost-effectiveness paradigm as-
sumes that addition of QALYs usually implicates higher
costs, as most cost-effectiveness analyses present better out-
comes at a higher cost [5]. This implies that healthcare costs
need to rise endlessly, in order to improve outcomes. The
limitations of CEA are discussed in the literature for at least
two decades, and have been shown to contradict welfare
economic principles, especially under budget constraints
[11]. Also, the use of the incremental cost-effectiveness ratio
(ICER), has been criticized for increasing expenditures on
healthcare technologies in an unsustainable manner [12],
and it was argued that it may not the right tool to make the
best use of healthcare resources [13].
Current CEA do not provide sufficient information on
which interventions should be utilized to maximize popu-
lation’s health outcomes, as they estimate the “value for
money” for an “average” typical patient, ignoring the asso-
ciated budget consequences (i.e., affordability), and also ig-
noring how patients might differ from one another in their
benefits and/or treatment costs [14]. Since the vast major-
ity of innovative medical interventions are associated with
better outcomes, but also with increased costs when com-
pared to the standard of care, adopting these interventions
in routine clinical practice may frequently result in a need
for very high additional budgets, especially when these
treatments are targeted at a large patient population. This
challenge has been recently demonstrated by the new ther-
apies for Hepatitis C virus (HCV). New therapies for HCV
show cure rates of 90 % and higher [15], with the cost of
therapy is between $66,000 and $84,000 per patient in the
US [16]. While cost-effectiveness analyses have shown fa-
vorable ICERs for these therapies in Spain [17], France
[18] and prisoner population in the US [19]. However,
treating 184,000,000 HCV patients worldwide, seems sim-
ply unaffordable [20].
As continued increase in health expenditures is no
longer sustainable in many countries and there is a clear
global need for a policy that will improve health outcomes,
without increasing healthcare costs. From a societal per-
spective, when resources are constrained, the fundamental
goal of innovation should not be restricted to an improve-
ment on the best available option. Rather, in a setting in
which some do not have access to the “best” technology,
more aggregate health benefits may be achieved from a
policy allowing a widespread diffusion of effective alterna-
tives, albeit not the best ones. There is a clear need for an
economic model that would account for the total health
benefits for the entire intended-use (IU) population, under
a constrained budget.
Coping with limitations of cost-effectiveness analysis
Another important component of HTA is the budget im-
pact analysis that assesses the financial consequences of
the introduction of a new technology in a specific setting
in the short-to-medium term [21]. Budget impact analysis
is supposed to be complementary to more established
types of economic evaluations, mainly cost-effectiveness
analysis, by providing decision-makers with additional in-
formation on the financial consequences of covering and
reimbursing new technologies. Thus, the outcomes of the
budget impact analysis should reflect scenarios that con-
sist of a set of specific assumptions and data inputs of
interest to the decision-maker rather than a scientifically
chosen “base” or “reference” case as is usually done in the
CEA. Decision makers need to take into account both the
cost –effectiveness of and the affordability of technologies,
and it has been suggested to use an “affordability curve”
[22] for this purpose. Another method is to try to optimize
the health gains under a constrained budget. An early ap-
proach in this regard was used for treating cardiovascular
disease in Sweden [23]. The authors tried to maximize the
health gains, i.e. primary prevention of cardiovascular
events, by calculating the optimal distribution of a fixed
budget among drug treatment of hypertension, drug treat-
ment of cholesterol and life-style intervention. A trad-
itional league table method was used to divide the budget
among these treatment options. All interventions were
ranked by their ICER and a cut-off line was drawn when
the budget was exhausted. In a more recent analysis, the
authors used a Markov model to synthesize clinical and
economic evidence and to compute population-level costs
and effects of interventions in the psychiatry field [24].
The model compared a base case scenario without pre-
ventive telemedicine and alternative scenarios with pre-
ventive telemedicine. The primary outcome measure was
the benefit-to-cost ratio, or return-on-investment (ROI).
The researchers ran a scenario that kept the healthcare
budget constant, in which the costs of offering preventive
telemedicine were balanced by reducing the expenditures
for curative interventions. The results demonstrated that a
system with preventive telemedicine for depressive
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disorders offers better ROI than a healthcare system with-
out it. A more comprehensive approach to optimize a full
portfolio of healthcare programs under a fixed budget was
suggested, by using a complex mathematical model [25].
The authors demonstrated the importance of taking
budgetary considerations and uncertainty into account
when making decisions and decision rules.
All of these models are yet to be implemented in a real
world setting, perhaps as a result of their complexity.
Therefore, our objective was to develop a practical
framework that can assist decision-makers in comparing
the impact of intervention alternatives on the entire tar-
get population, under a pre-specified budget constraint.
Methods
Mathematical model
We define the upper limit of the number of patients that
can be assigned to a specific alternative v as the PTPv
(potentially treated population). We define Cv as the dir-
ect annual cost of a specific alternative, per patient, and
B as the annual budget limit. Now, we can calculate the
upper limit of the number of patients that can be treated




If we denote the overall efficacy of each intervention as
Ev, we can calculate the total events prevented by using
intervention v, denoted PEPv as shown in Equation 2:
PEPv ¼ Ev PTPv ð2Þ
We can calculate PEPv as a function of Ev, Cv and B,
as shown in Equation 3:
PEPv ¼ Ev PTPv ¼ Ev  B
Cv
ð3Þ
Since B is constant, the ratio between PEP2 and PEP1


















The implication is that in order for a more expensive ther-
apy to be more effective on the entire population, its relative
effectiveness has to be higher than its relative market price.
We can also use Equation 4 to calculate the breakeven
cost for a new intervention C2, by defining that PEP1 =
PEP2. Using Equation 4 we can receive Equation 5:
PEP1
PEP2




¼¼> C1 ¼ E1
E2
 C2 ð5Þ
Assuming we know the ratio of superiority of E1 over
E2, we can calculate the breakeven price for the expensive/
effective intervention. For example, if E1 is 20 % higher
than E2, than in up to 20 % higher cost it will provide bet-
ter outcomes for the IUP, and in any cost higher than that
it would provide inferior outcomes for the IUP. For com-
parison, the conventional ICER, which does not take into
account budget constraints, is calculated as follows: C2−C1E2−E1
Therefore, while the high cost/high effectiveness inter-
vention may have an acceptable ICER, it could provide
inferior outcomes under budget constraints, depending
on the ratios between the efficacies and the costs of the
two interventions.
Model assumptions
We make the following assumptions in our model, in
order to maintain its simplicity:
The budget B is fixed.
The two interventions are mutually exclusive.
Total costs include intervention costs, and potential
cost offsets.
QALYs and costs are discounted to present values.
Results and discussion
Results
We demonstrate the model by using a hypothetical sce-
nario in which the target population (IUP) includes 1,000
patients, and the budget constraint B is $1,000,000. We
compared two interventions: the current technology (V =
1) that costs $1,000 per patient, and adds 0.5 QALY per
patient and a new technology (V = 2) that costs 100 %
more, and provides 20 % more QALYs per patient. Table 2
presents the values derived for the demo case.
The ICER is calculated as follows: C2−C1E2−E1 : In this case,
the ICER is 2;000−1;0000:6−0:5 ¼ $10; 000: This ICER is well
below the accepted thresholds [9] and according to the
current paradigm we should adopt the new technology,
as it provides good value for money. However, in our
proposed model which takes into account the budget
constraint, we observe a significant reduction in the
overall population outcomes, as 200 QALYs will be lost
if we prefer the new technology. Using equation 5, we
Table 2 Results of the demo case study
Model Parameters/Intervention Acronym V = 1 V = 2 Delta
Budget Constraint ($US) B 1,000,000 1,000,000 0
Cost per patient ($US) C 1000 2,000 1000
Potentially Treated Population PTP 1000 500 −500
Untreated Population UTP 0 500 500
Effectiveness- as measured by
added QALY per patient
E 0.50 0.60 0.10
QALYs added for the entire IUP PEP 500 300 −200
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 C2 ¼ 0:6
0:5
 $1; 000 ¼ $1; 200 ð6Þ
This price, as we demonstrated, is directly correlated
to the effectiveness premium of the new technology,
which in this case is 20 %.
Discussion
In this study, we first reviewed the limitations of current
health technology assessment models in providing
decision-makers with tools that may assist them in maxi-
mizing population’s health outcomes under restricted bud-
gets. We developed an analytic framework for comparing
and assessing the impact of alternative interventions under
pre-specified budget constraints. The mathematical analysis
performed revealed that the added price worth paying for
superior efficacy is directly related to the superior outcomes
we expect to receive from the higher efficacy intervention.
This insight differs significantly from traditional cost-
effectiveness analysis, which may accept a much higher cost
of a new therapy as being cost-effective and economically
acceptable, as long as it has an acceptable ICER. Our ap-
proach resembles in this aspect the approach taken by the
German Institute for Quality and Efficiency in healthcare
(IQWiG), asserting that the additional costs and benefits of
an intervention should be compared only to alternatives for
the same indication [14]. IQWiG has used the efficiency
frontier approach to represent the best outcomes that the
healthcare system can achieve at current prices and effica-
cies of the alternative interventions. However, a major dis-
tinction exists between our proposed concept and the
German approach; IQWiG is willing to consider innovative
interventions only if they provide superior benefits per pa-
tient over the existing intervention alternatives. This ap-
proach follows the rationale that physicians are obliged to
provide the best available medicine to their patients, but
may prevent achieving equity in adoption of medical inno-
vations. Buchanan et al. (27) use medical therapies as one
of the best examples of injustice of innovation. They claim
that justice in innovation is not restricted to the just distri-
bution of existing beneficial innovations, for two reasons.
First, as the case of essential medicines makes clear, the fact
that important innovations are not occurring can be a con-
cern of justice. If justice implies a human right to health-
care, this situation is unjust. Medicines that could save the
lives of millions of people in these countries, at relatively
low cost are not being developed. The conclusions of the
PURE study (5), that mainstream adoption of low cost in-
terventions could provide better outcomes for the target
population, despite providing less than optimal therapy at
the individual patient level, are in line with our objective
and thesis.
Model limitations
Our suggested approach may have several limitations.
First, it has a major limitation when compared to the
standard cost-effectiveness analysis as it compares therap-
ies for a specific target population. CEA can assist in re-
source allocation among competing interventions for
various disease areas and interventions, using a common
outcome metric (e.g. QALY). However, the model could
be extended to compare the outcomes of different target
populations, by comparing the added QALYs achieved in
each target population. Our approach has been used by
the German healthcare system, which evaluates innovative
interventions only in comparison to true alternatives for
the same intended use population [26]. Our model uses
only direct healthcare costs, and did not account for indir-
ect costs, as is sometimes done in CEA. The rational was
that the perspective taken here is of the payer who holds
the budget, and the guidelines for budget impact analyses
suggest modeling only direct costs [21]. It is possible, how-
ever, to extend the model to include indirect costs as well.
For reasons of simplicity, we have not included in the
model various parameters that may have a significant im-
pact on costs and outcomes, such as adoption rates of the
interventions, adherence, horizon of therapy and eco-
nomic analyses and risk factors. It is possible to extend the
model to include these parameters, and perform various
sensitivity analyses on these parameters accordingly.
It may seem that our suggested model may under-
estimate the value of an expensive intervention with
long-term effects such as an effective vaccination, as a
result of our focus on a fixed budget. However, assuming
that the payer uses our proposed model with a relatively
long term horizon to inform decisions, the model will
demonstrate the benefits of herd immunity when fewer
cases are arising each year.
Notwithstanding these limitations, our proposed frame-
work may have important policy and industry implica-
tions. Since widespread diffusion of innovation is critical
in order to make a significant impact on public health,
payers must consider the effect of budget and price on
market access to innovation.
Conclusions
Our proposed framework may have important policy and
industry implications. The model provides a method for
evaluating the health effects of treatment alternatives on an
entire IUP, under a constrained budget. In the current cost-
effectiveness paradigm, technologies are rated according to
their ICER for a base case where an incremental cost over
an incremental benefit is presented. This approach can en-
sure that the effectiveness of various technologies can be
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compared on the entire IUP. Since widespread diffusion of
innovation is critical in order to make a significant impact
on public health, payers must consider the effect of budget
and price on market access to innovation. Although an
intervention associated with higher costs and better out-
comes may have an acceptable ICER, it could provide infer-
ior outcomes under budget constraints, depending on the
relative effectiveness and costs of the two interventions, as
was suggested in the literature [27]. Fig. 2 illustrates the re-
sults in the demo scenario:
Moreover, higher costs of a drug may imply higher co-
payments, which have a negative effect on adherence
[28], and thus a negative impact on outcomes, as adher-
ence has a significant impact on outcomes, as has been
shown to be the case in secondary prevention post myo-
cardial infarction [29]. The cost premium that can be
justified for a more effective intervention is directly cor-
related to the effectiveness premium of that intervention
over the lower cost/lower effectiveness intervention. In
cases that a new technology does provide better out-
comes for the intended use population, disinvestment in
the old technology would be required.
The proposed policy could be applied to various tech-
nologies in various countries, in order to assist policy
makers and payers to maximize the health outcomes of
various intended use populations. The research should be
carried out for each country separately, because of differ-
ent patient populations, and different pricing schemes.
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